TSHA Overview

Key Data

  • Open $24.80
  • Day Range 23.37 - 24.80
  • 52 Week Range 18.16 - 33.35
  • Market Cap $902.06M
  • Shares Outstanding 37.92M
  • Public Float 19.89M
  • Beta 1.42
  • Rev. per Employee N/A
  • P/E Ratio N/A
  • EPS -$2.78
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 1.42M 05/14/21
  • % of Float Shorted 7.12%
  • Average Volume 121.46K

Performance

5 Day
  • 7.16%
1 Month
  • 13.29%
3 Month
  • -10.56%
YTD
  • -10.36%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8 Full Ratings

Recent News

  • MarketWatch
  • Dow Jones

Taysha Gene Therapies started at outperform with $31 stock price target at Wedbush

Jun. 9, 2021 at 8:25 a.m. ET by Tomi Kilgore
Barron's

Four Biotech Companies Are Going Public Today. What to Know About Each.

Sep. 24, 2020 at 3:26 p.m. ET by Barron's
Barron's

Biotech Taysha Gene Therapies Climbs in Trading Debut

Sep. 24, 2020 at 10:52 a.m. ET by Barron's

Taysha Gene Therapies sets IPO terms, could be valued at up to $690.4 million

Sep. 17, 2020 at 6:56 a.m. ET by Tomi Kilgore

Taysha Gene Therapies sets IPO terms, to raise up to $131.6 million

Sep. 17, 2020 at 6:46 a.m. ET by Tomi Kilgore
  • Other News
  • Press Releases

Taysha Gene Therapies, Inc. (TSHA) Q1 2021 Earnings Call Transcript

May. 11, 2021 at 8:00 p.m. ET on Motley Fool

Taysha Gene Therapies (TSHA) Receives a Buy from William Blair

May. 11, 2021 at 1:25 p.m. ET on SmarterAnalyst

Oppenheimer Maintains Their Buy Rating on Taysha Gene Therapies (TSHA)

May. 10, 2021 at 1:35 p.m. ET on SmarterAnalyst

Company News for Apr 13, 2021

Apr. 13, 2021 at 9:54 a.m. ET on Zacks.com

Morgan Stanley Remains a Buy on Taysha Gene Therapies (TSHA)

Apr. 13, 2021 at 8:26 a.m. ET on SmarterAnalyst

Taysha Gene Therapies (TSHA) Receives a Rating Update from a Top Analyst

Apr. 12, 2021 at 11:15 a.m. ET on SmarterAnalyst

William Blair Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

Apr. 12, 2021 at 9:45 a.m. ET on SmarterAnalyst

Taysha Gene Therapies Inc. (TSHA) Q4 2020 Earnings Call Transcript

Mar. 19, 2021 at 2:20 p.m. ET on Motley Fool

Taysha Gene Therapies (TSHA) Gets a Buy Rating from Oppenheimer

Mar. 16, 2021 at 6:55 p.m. ET on SmarterAnalyst

William Blair Maintains Their Buy Rating on Taysha Gene Therapies (TSHA)

Mar. 9, 2021 at 9:20 a.m. ET on SmarterAnalyst

Analysts Are Bullish on Top Healthcare Stocks: Taysha Gene Therapies (TSHA), Strongbridge Biopharma (SBBP)

Mar. 3, 2021 at 4:25 p.m. ET on SmarterAnalyst

William Blair Remains a Buy on Taysha Gene Therapies (TSHA)

Mar. 3, 2021 at 12:35 p.m. ET on SmarterAnalyst

Taysha Gene Therapies (TSHA) Receives a Buy from William Blair

Feb. 24, 2021 at 4:04 a.m. ET on SmarterAnalyst

Taysha Gene Therapies (TSHA) Receives a Buy from Oppenheimer

Feb. 9, 2021 at 12:05 p.m. ET on SmarterAnalyst

Oppenheimer Releases a Buy Rating on Taysha Gene Therapies (TSHA)

Jan. 13, 2021 at 11:35 p.m. ET on SmarterAnalyst

Taysha Gene Therapies (TSHA) Received its Third Buy in a Row

Nov. 13, 2020 at 1:15 p.m. ET on SmarterAnalyst

Taysha Gene Therapies Inc.

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.